Transgenic mouse expressing human mutant α-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease

This publication has 23 references indexed in Scilit:

• A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity
  Trends in Pharmacological Sciences, 2003
• Alternative Splicing in the α-Galactosidase A Gene: Increased Exon Inclusion Results in the Fabry Cardiac Phenotype
  American Journal of Human Genetics, 2002
• Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
  New England Journal of Medicine, 2001
• A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety Studies
  American Journal of Human Genetics, 2001
• Fabry Disease: Preclinical Studies Demonstrate the Effectiveness of α-Galactosidase A Replacement in Enzyme-Deficient Mice
  American Journal of Human Genetics, 2001
• Correction of Enzymatic and Lysosomal Storage Defects in Fabry Mice by Adenovirus-Mediated Gene Transfer
  Human Gene Therapy, 1999
• Heart-specific activation of LTK results in cardiac hypertrophy, cardiomyocyte degeneration and gene reprogramming in transgenic mice
  Oncogene, 1999
• Aggregation of the Inactive Form of Human α-Galactosidase in the Endoplasmic Reticulum
  Biochemical and Biophysical Research Communications, 1996
• An Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy
  New England Journal of Medicine, 1995
• Human α-galactosidase gene expression: significance of two peptide regions encoded by exons 1–2 and 6
  Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1994